About Absynth Biologics

Absynth develops vaccines to prevent bacterial infections to address the challenge of antimicrobial resistance. Prevention of infections directly reduces the need for antibiotics and prophylactic vaccines have never induced resistance. Absynth’s vaccines target Staphylococcus aureus and Clostridium difficile, the cause of damage to health or death. Absynth is competitively placed with a suite of novel protein vaccine antigens that differ from and offer possible benefits over competitor products.

Business Model

Absynth’s business model is to establish a vaccine pipeline targeting a range of infectious diseases and secure partnerships when it has preclinical or clinical proof of principle. Potential partners are pharmaceutical companies with proven expertise to advance vaccines to market. Absynth will licence products in return for milestone and royalty payments, which could lead to a trade sale.

Market & Competition

There currently are no marketed vaccines for S. aureus or C.difficile infections (CDI), which are treated with antibiotics., that are subject to increase in resistance. The estimated market for an S. aureus vaccine for elective surgery patients is >$1 bill, with elective surgery a primary target group as post-operative infections result in prolonged hospital stays and increased morbidity and mortality. C. difficile has become one of the most common healthcare-associated infections. In 2011 in the USA it is estimated CDI caused >450,000 infections and was associated with 29,000 deaths, while in Europe extrapolating from English data; ~172,000 cases may occur each year across the EU member states. Competition: Four S. aureus vaccines reached the clinic recently: from Pfizer, GSK, Novadigm and Alopexx.  All use capsular antigens typical of those that have failed before and Pfizer and Alopexx are the only trials currently active. For C. difficile there are three vaccines at clinical stage: from Pfizer, Sanofi Pasteur and Valneva but only Sanofi’s trial is currently active (Phase 3). All comprise C.difficile secreted toxins A and B, which appear to be effective, but 30 – 40 of patients do not respond. Absynth’s vaccine has potential to provide more complete responses and in addition, unlike toxin-based vaccine candidates, it should prevent clostridial colonisation by spore-mediated transmission of C.difficile and those vaccinated could be less likely to become asymptomatic carriers.


Absynth patents are granted in all major territories, which underpin the value in our business
Dr Fiona Marston, Chief Executive
Back to Top